Benlysta First Agent Approved for Lupus Nephritis: GlaxoSmithKline announced yesterday that the FDA has approved belimumab (Benlysta) for use in adults with active lupus nephritis (LN) receiving background/standard therapy. https://t.co/O7CBAn55t2 https://t.co/RWNDzUqxhM